



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,887	12/15/2005	Christopher McGuigan	1493-140 US	3648
26817 7590 10/01/2008 MATHEWS, SHEPHERD, MCKAY, & BRUNEAU, P.A. 29 THANET ROAD, SUITE 201 PRINCETON, NJ 08540				
EXAMINER MCINTOSH III, TRAVIS C				
ART UNIT		PAPER NUMBER		
1623				
MAIL DATE		DELIVERY MODE		
10/01/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/560,887

Applicant(s)

MCGUIGAN, CHRISTOPHER

Examiner

TRAVISS C. MCINTOSH III

Art Unit

1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 25 May 2006.
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-40 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 1-40 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SF/08)
Paper No(s)/Mail Date 12/15/05 & 5/25/06
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____

DETAILED ACTION

Specification

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 21-23 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for treating cancer, does not reasonably provide enablement for prevention or the prophylaxis of the same. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

Undue experimentation is a conclusion reached by weighing the noted factual considerations set forth below as seen in *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988). A conclusion of lack of enablement means that, based on the evidence regarding a fair evaluation of an appropriate combination of the factors below, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation.

These factors include:

- (A) The breadth of the claims;

Art Unit: 1623

- (B) The nature of the invention;
- (C) The state of the prior art;
- (D) The level of one of ordinary skill;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;
- (G) The existence of working examples; and
- (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

The breadth of the claims - The nature of the invention

The claims are drawn to compounds for and methods of treating or preventing cancer.

The state of the prior art

Compounds having a similar core structure, such as gemcitabine, are known to be effective in treating various cancers, such as treating non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer (see Wikipedia for Gemcitabine). At present, there are no known agents capable of preventing cancer.

The level of predictability in the art

The examiner acknowledges the probability and predictability that the active agent has efficacy in treating certain conditions associated with cancer, however the art is silent with regard to the predictability of effectively preventing the development of cancer by administering any of various agents.

The amount of direction provided by the inventor

The instant specification is not seen to provide adequate guidance which would allow the skilled artisan to extrapolate from the disclosure and examples provided to use the claimed method commensurate in the scope with the instant claims. There is a lack of data and examples which adequately represent the scope of claim as written. The examiner notes, there has not been

provided sufficient instruction or sufficient methodological procedures to support the alleged efficacy instantly asserted.

The existence of working examples

The working examples set forth in the instant specification are directed to the various mouse models using xenografts of human cancer (colon HT115 and prostate PC3) and also cytotoxicity tests using human colon cancer cell line HT115, breast cancer cell line MDA MB231, and prostate cancer cell line PC-3. There has not been provided sufficient evidence which would warrant the skilled artisan in oncology, to accept the data and information provided in the working examples as correlative proof that a healthy individual would never become afflicted with any cancerous condition if subjected to the instantly claimed therapy.

The quantity of experimentation needed to make and use the invention based on the content of the disclosure

Indeed, in view of the information set forth supra, the instant disclosure is not seen to be sufficient to enable the use of any claimed compound or composition to prevent the development of cancer without undue experimentation. One skilled in the art could not use the entire scope of the claimed invention without undue experimentation.

Reasonable guidance with respect to preventing any cancer relies on quantitative analysis from defined populations which have been successfully pre-screened and are predisposed to particular types of cancer. This type of data might be derived from widespread genetic analysis, cancer clusters, or family histories. The essential element towards the validation of a preventive therapeutic is the ability to test the drug on subjects monitored in advance of clinical cancer and *link* those results with subsequent histological confirmation of the presence or absence of

disease. This irrefutable link between antecedent drug treatment and subsequent knowledge of the prevention of the disease is the essence of verification of a valid preventive agent. For example, Byers, T. (CA Journal, Vol. 49, No. 6, Nov/Dec. 1999) teaches that randomized controlled trials are commonly regarded as the definitive study for proving causality (1st col., p.358), and that in controlled trials the random assignment of subjects to the intervention eliminates the problems of dietary recalls and controls the effects of both known and unknown confounding factors. Further, Byers suggests that chemo-preventative trials be designed "long-term" such that testing occurs over many years (2nd col., p. 359). The specification is devoid of any models or experimental analysis that reasonably suggests that the claimed method would predictably prevent the formation of tumors in a mammal. This, combined with the state of the art of preventing cancer, suggests that undue experimentation would be required to practice the invention as broadly claimed

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In various instances, such as in claim 1, applicants have used phrases such as "and methyl (-CH₃)", in defining X and Y, and R' and R"; or "unsubstituted phenyl (-C₆H₅)". The use of these parenthetical phrases which encompass the chemical formula is confusing, as it is unclear if applicants intend methyl to be linked to another methyl group, or phenyl is linked to another

phenyl group, etc. The use of the chemical formula and its chemical name together is seen to be redundant and confusing as it is unclear what applicants actually intend. This is indefinite in all instances, such as in claims 3, 7, 22, etc.

Claim 1 includes the limitation of various groups being “optionally **substituted**”. In the absence of the identity of moieties which are intended to be substituted, thus modifying an art recognized chemical core, described structurally or by chemical name, the identity of “substituted” would be difficult to ascertain. In the absence of said moieties, the claims containing the term “substituted” are not described sufficiently to distinctly point out that which applicant intends as the invention. This is indefinite in all instances, such as in claims 5, 14, etc.

Claim 1 is drawn to compounds or a pharmaceutically acceptable “derivative or metabolite” thereof. In the absence of the identity of moieties intended to modify an art recognized chemical core, described structurally or by chemical name, the identity of a derivative would be difficult to ascertain. In the absence of said moieties, the claims containing the term “derivative” are not described particularly sufficiently to distinctly point out that which applicant intends as the invention. Likewise, absent explicit guidance, it is unclear what compounds would be encompassed by metabolites, as it is unclear which compounds would be and which would not be a metabolite of the instant compounds.

Claim 7 is indefinite wherein the claim provides that “R is selected from the group comprising alkyl, aryl, and alkylaryl, and H, R’, and R” are independently selected from the group comprising H, alkyl, and alkylaryl”. Is applicant intending H to optionally be alkyl or alkylaryl? It is noted the examiner has interpreted this as R optionally being H and not H being alkyl or alkylaryl.

Claim 12 recites the limitation "wherein the carbocyclic ring is a pentyl ring". There is insufficient antecedent basis for this limitation in the claim. Claim 9, that from which claim 12 depends, does not recite a carbocyclic ring. The claim provides that R' and R" can optionally be a C₅₋₆ ring, but this is not the same as "the carbocyclic ring". When looking back at the claims from which claim 9 depends, it is noted there are various possible "carbocyclic rings" and it is unclear which ones applicants intend to limit to only a pentyl ring (Ar can also be a carbocyclic ring).

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 21 recites the broad recitation "for use in a method of treatment", and the claim also recites "preferably in the prophylaxis or treatment of cancer" which is the narrower statement of the range/limitation.

Claim 20 is confusing where none of the compounds listed are separated by any punctuation.

Claim 22 provides for the use of a compound of claim 1, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

All claims which depend from an indefinite claim are also indefinite. *Ex parte Cordova, 10 U.S.P.Q. 2d 1949, 1952 (P.T.O. Bd. App. 1989).*

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 22 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-40 are rejected under 35 U.S.C. 102(b) as being anticipated by Shepard et al. (US 2003/0109697).

Shepard et al. disclose compounds which meet the limitations of those instantly claimed, and methods of treating cancer with the same. See claim 1 for example, where R₁ is H or alkyl and claim 29 in treating cancer. Claim 24 of the '697 document is seen to be the same compound as compound CPF 35 of claim 20 of the instant application.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C. MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached on M-F 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Traviss C McIntosh III/
Art Unit 1623
September 25, 2008